Very deep prostate-specific antigen decline is associated with longer rPFS in patients with metastatic castration-sensitive prostate cancer.

ABSTRACT:

Background

Prostate-specific antigen (PSA) is widely used in the diagnosis and monitoring of prostate cancer. The prognostic relevance of very low PSA levels has not been clearly established in metastatic castration-sensitive prostate cancer (mCSPC). More sensitive PSA assays may provide more accurate estimates of clinical outcomes.

Objectives

To evaluate the relationship between achieving very deep PSA levels (⩽0.02 ng/mL) within 6 months of treatment and radiologic progression-free survival (rPFS) in patients with mCSPC.

Design

A retrospective, unicenter observational study conducted at a tertiary oncology center.

Methods

A total of 203 patients with mCSPC who received first-line treatment with luteinizing hormone-releasing hormone analogs, androgen receptor

SUBMITTER: Kapar C 

PROVIDER: S-EPMC12391712 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature